Breaking News Instant updates and real-time market news.

XLRN

Acceleron

$47.34

0.58 (1.24%)

07:10
07/10/18
07/10
07:10
07/10/18
07:10

Acceleron price target raised to $74 from $69 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised his price target for Acceleron Pharma to $74 citing the positive results from the Phase 3 Believe study of luspatercept in transfusion-dependent beta-thalassemia patients. The analyst expects sales in 2020 of $31M, growing to $260M in 2026. He keeps a Buy rating on Acceleron.

XLRN Acceleron
$47.34

0.58 (1.24%)

06/29/18
GSCO
06/29/18
UPGRADE
Target $40
GSCO
Neutral
Acceleron upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Terence Flynn upgraded Acceleron Pharma (XLRN) to Neutral and raised his price target for the shares to $40 from $21. The stock in premarket trading is up 26.5%, or $9.02, to $43.00. The Luspatercept Phase 3 myelodysplastic syndromes trial achieved a "highly" statistically significant improvement on the primary endpoint - transfusion independence compared to placebo, Flynn tells investors in a research note following last night's announcement. Following the trial success, the analyst expects the focus to shift increasingly to the drug's commercial opportunity. He raised his probability of success for Luspatercept to 90% from 75% in myelodysplastic syndromes and beta-thal. While the beta-thal Phase 3 trial is still ongoing, the safety commentary in the MDS trial release was a positive, Flynn argues. The analyst keeps a Sell rating on Acceleron's Luspatercept partner Celgene (CELG) while boosting his price target for the shares to $82 from $81. Celgene still needs to deliver on a number of upcoming pipeline events, Flynn says.
06/29/18
JPMS
06/29/18
NO CHANGE
Target $54
JPMS
Overweight
Acceleron shares have 30%-35% upside on 'clean win,' says JPMorgan
In a research note partially titled "Gooooal! A Clean Win for MEDALIST Phase 3," JPMorgan analyst Eric Joseph raised his price target for Acceleron Pharma to $54 from $52. While details on specific endpoints were light, the top-line announcement notes highly significant outcomes on both primary and key secondary endpoint, Joseph writes. The analyst views the outcome as a "clean win" that and "materially de-risks" the path forward to approval for luspatercept. He sees 30%-35% upside to current levels for Acceleron shares on higher probability of success assumptions across Street models on myelodysplastic syndromes alone. Joseph keeps an Overweight rating on Acceleron. The stock in premarket trading is up 26.5% to $43.00.
07/10/18
PIPR
07/10/18
DOWNGRADE
Target $52
PIPR
Neutral
Acceleron downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Acceleron Pharma (XLRN) to Neutral and lowered his price target for the shares to $52 from $55. Acceleron and partner Celgene (CELG) last night announced positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia, Tenthoff tells investors in a research note. The stock in premarket trading is up $6.10, or 13%, to $53.50. This is a nice second win for luspatercept, but Acceleron shares are not a buy at current valuation levels, the analyst contends. He believes luspatercept does not command the same market opportunity in beta thalassemia due to the expected approval of curative gene therapy by 2020. As such, Tenthoff lowered his penetration rates for luspatercept in beta thal to account for gene therapy competition. He says, however, that partner Celgene could acquire Acceleron, which presents a risk to his downgrade.
07/10/18
UBSW
07/10/18
NO CHANGE
Target $62
UBSW
Buy
Acceleron price target raised to $62 from $57 at UBS
UBS analyst Carter Gould raised his price target for Acceleron Pharma to $62 citing the positive results from the Phase 3 Believe study of luspatercept in beta-thalassemia. While not a surprise after the positive Medalist data two weeks ago, a "clear clinical win" was important given a lack of quantitative details in either press release, Gould tells investors in a research note. He keeps a Buy rating on Acceleron.

TODAY'S FREE FLY STORIES

23:10
10/17/18
10/17
23:10
10/17/18
23:10
General news
Asia Market Action: equities are mixed »

Asia Market Action:…

PHAS

PhaseBio

$0.00

(0.00%)

21:06
10/17/18
10/17
21:06
10/17/18
21:06
Syndicate
PhaseBio 9.2M share IPO priced at $5.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

MSC

Studio City

$0.00

(0.00%)

21:00
10/17/18
10/17
21:00
10/17/18
21:00
Syndicate
Studio City 28.75M share IPO priced at $12.50 »

The deal was priced at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BHGE

Baker Hughes

$30.75

-0.09 (-0.29%)

, CJ

C&J Energy Services

$20.40

-0.12 (-0.58%)

20:38
10/17/18
10/17
20:38
10/17/18
20:38
Recommendations
Baker Hughes, C&J Energy Services, FTS International, Halliburton, Keane Group, Nabors Industries, Nine Energy Services, Patterson-UTI, ProPetro Holding, Schlumberger, Covia , Helmerich & Payne, U.S. Silica, Weatherford analyst commentary at BofA/Merrill »

BofA/Merrill reinstating…

BHGE

Baker Hughes

$30.75

-0.09 (-0.29%)

CJ

C&J Energy Services

$20.40

-0.12 (-0.58%)

FTSI

FTS International

$12.87

-0.115 (-0.89%)

HAL

Halliburton

$39.56

-0.52 (-1.30%)

FRAC

Keane Group

$12.50

-0.14 (-1.11%)

NBR

Nabors Industries

$6.25

-0.175 (-2.72%)

NINE

Nine Energy Services

$39.10

0.31 (0.80%)

PTEN

Patterson-UTI

$16.58

-0.37 (-2.18%)

PUMP

ProPetro Holding

$18.19

-0.315 (-1.70%)

SLB

Schlumberger

$59.24

-0.43 (-0.72%)

CVIA

Covia

$7.01

-0.57 (-7.52%)

HP

Helmerich & Payne

$68.06

-1.13 (-1.63%)

SLCA

U.S. Silica

$17.69

-1.03 (-5.50%)

WFT

Weatherford

$2.61

-0.03 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

PM

Philip Morris

$84.62

1.12 (1.34%)

, DHR

Danaher

$104.95

-0.13 (-0.12%)

20:25
10/17/18
10/17
20:25
10/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PM

Philip Morris

$84.62

1.12 (1.34%)

DHR

Danaher

$104.95

-0.13 (-0.12%)

BK

BNY Mellon

$49.16

-0.17 (-0.34%)

NVS

Novartis

$85.34

-0.41 (-0.48%)

BX

Blackstone

$36.06

-0.02 (-0.06%)

BBT

BB&T

$47.73

0.64 (1.36%)

TRV

Travelers

$126.47

1.75 (1.40%)

PPG

PPG

$98.15

-0.06 (-0.06%)

KEY

KeyCorp

$18.75

0.17 (0.91%)

NUE

Nucor

$59.11

0.17 (0.29%)

TXT

Textron

$64.72

-2.01 (-3.01%)

GPC

Genuine Parts

$95.26

-1.83 (-1.88%)

DOV

Dover

$82.28

-0.95 (-1.14%)

WBC

Wabco

$103.09

-6.91 (-6.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 16

    Nov

  • 13

    Dec

  • 18

    Oct

AVMXY

Avita Medical

$0.00

(0.00%)

19:55
10/17/18
10/17
19:55
10/17/18
19:55
Hot Stocks
Avita Medical announces first U.S. sales of Recell system »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRAC

Keane Group

$12.50

-0.14 (-1.11%)

19:33
10/17/18
10/17
19:33
10/17/18
19:33
Initiation
Keane Group initiated at BofA/Merrill »

Keane Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NBR

Nabors Industries

$6.25

-0.175 (-2.72%)

19:28
10/17/18
10/17
19:28
10/17/18
19:28
Initiation
Nabors Industries initiated at BofA/Merrill »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

NINE

Nine Energy Services

$39.10

0.31 (0.80%)

19:19
10/17/18
10/17
19:19
10/17/18
19:19
Initiation
Nine Energy Services initiated at BofA/Merrill »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

PTEN

Patterson-UTI

$16.58

-0.37 (-2.18%)

19:17
10/17/18
10/17
19:17
10/17/18
19:17
Initiation
Patterson-UTI initiated at BofA/Merrill »

Patterson-UTI initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

GSBC

Great Southern Bancorp

$52.51

0.26 (0.50%)

19:04
10/17/18
10/17
19:04
10/17/18
19:04
Earnings
Great Southern Bancorp reports preliminary Q3 EPS $1.18, consensus $1.06 »

Reports Q3 NI $43.0M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

HMNY

Helios and Matheson

$0.02

0.001 (5.18%)

18:59
10/17/18
10/17
18:59
10/17/18
18:59
Periodicals
Breaking Periodicals news story on Helios and Matheson »

Helios & Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BY

Byline Bancorp

$21.33

0.02 (0.09%)

18:51
10/17/18
10/17
18:51
10/17/18
18:51
Hot Stocks
Byline Bancorp to acquire Oak Park River Forest Bankshares for $42M »

Byline Bancorp and Oak…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ABB

ABB

$21.37

-0.115 (-0.54%)

18:48
10/17/18
10/17
18:48
10/17/18
18:48
Periodicals
ABB weighs divesting $10B power grid business, Bloomberg reports »

ABB is working with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEC

Vectrus

$28.98

-0.74 (-2.49%)

18:22
10/17/18
10/17
18:22
10/17/18
18:22
Hot Stocks
Vectrus names Kevin Boyle chief legal officer »

Vectrus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$6.41

-0.005 (-0.08%)

18:21
10/17/18
10/17
18:21
10/17/18
18:21
Hot Stocks
Sprint extends credits to Florida customers impacted by Hurricane Michael »

Sprint said it continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TALO

Talos Energy

$29.85

-1.49 (-4.75%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Talos Energy reaches pact with Hokchi to cross-assign interests »

Talos Energy Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Steel Dynamics CEO says 'delivered a tremendous third quarter performance' »

"The team delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:02
10/17/18
10/17
18:02
10/17/18
18:02
Hot Stocks
Steel Dynamics CEO: We believe steel consumption will continue to be strong »

"We remain confident…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:01
10/17/18
10/17
18:01
10/17/18
18:01
Earnings
Steel Dynamics reports Q3 adjusted EPS $1.69, consensus $1.64 »

Reports Q3 revenue $3.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CRTO

Criteo

$23.00

-0.29 (-1.25%)

, RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

17:44
10/17/18
10/17
17:44
10/17/18
17:44
Periodicals
Advertising technology firm DataXu exploring sale, WSJ says »

DataXu, which offers…

CRTO

Criteo

$23.00

-0.29 (-1.25%)

RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

FUEL

Rocket Fuel

$0.00

(0.00%)

GOOG

Alphabet

$1,115.99

-4.12 (-0.37%)

FB

Facebook

$159.46

0.65 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 15

    Nov

  • 16

    Nov

  • 03

    Mar

BTU

Peabody Energy

$36.09

-0.31 (-0.85%)

17:37
10/17/18
10/17
17:37
10/17/18
17:37
Hot Stocks
Peabody Energy increases quarterly dividend nearly 4% to 13c per share »

Peabody Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:34
10/17/18
10/17
17:34
10/17/18
17:34
Earnings
Brandywine Realty sees FY19 FFO $1.37-$1.47, consensus $1.44 »

Sees FY17 EPS 36c-46c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:33
10/17/18
10/17
17:33
10/17/18
17:33
Earnings
Brandywine Realty narrows FY18 FFO view to $1.36-$1.40 from $1.35-$1.41 »

Consensus for FY18 FFO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:32
10/17/18
10/17
17:32
10/17/18
17:32
Earnings
Brandywine Realty reports Q3 FFO 35c, consensus 35c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.